Progress and Prospects of Non-Canonical NF-κB Signaling Pathway in the Regulation of Liver Diseases

Li, Tao; Ren, Xiaomeng; Zhai, Wenhui; Chen, Zheng

doi:10.3390/molecules27134275

Cited by 10 publications

(3 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reduction in fibrosis is achieved by the activation of PPARα and PPARδ that lead to the inhibition of NF-κB and AP-1 pathways. These two pathways are related to liver damage and inflammation [ 69 , 70 , 71 ].…”

Section: Therapeutic Optionsmentioning

confidence: 99%

Current Therapies for Cholestatic Diseases

2023

View full text Add to dashboard Cite

Cholestasis is a condition characterized by decrease in bile flow due to progressive pathological states that lead to chronic cholestatic liver diseases which affect the biliary tree at the intrahepatic level and extrahepatic level. They induce complications such as cirrhosis, liver failure, malignancies, bone disease and nutritional deficiencies that merit close follow-up and specific interventions. Furthermore, as those conditions progress to liver cirrhosis, there will be an increase in mortality but also an important impact in quality of life and economic burden due to comorbidities related with liver failure. Therefore, it is important that clinicians understand the treatment options for cholestatic liver diseases. With a general view of therapeutic options and their molecular targets, this review addresses the pathophysiology of cholangiopathies. The objective is to provide clinicians with an overview of the safety and efficacy of the treatment of cholangiopathies based on the current evidence.

show abstract

Section: Therapeutic Optionsmentioning

confidence: 99%

Current Therapies for Cholestatic Diseases

2023

View full text Add to dashboard Cite

show abstract

“…The reduction fibrosis is achieved by the activation of PPARα and PPARδ that lead to the inhibition of NF-κB and AP-1 pathways. These two pathways are related to liver damage and inflammation [66,67].…”

Section: Ppar Agonists: Fibrates Seladelpar Elafibranormentioning

confidence: 99%

Current Therapies for Cholestatic Diseases

Méndez-Sánchez¹,

Coronel-Castillo²,

Ordoñez-Vázquez³

2023

Preprint

View full text Add to dashboard Cite

Cholestasis is a condition defined as an abnormal decrease of bile flow due to progressive pathological states or cholestatic liver diseases that affect the biliary tree at intrahepatic and extrahepatic level. It induces complications such as cirrhosis, liver failure, malignancies, pruritus, fatigue, bone disease and nutritional deficiencies that merit close follow-up and specific interventions to improve quality of life. Furthermore, cholestasis can progress to end-stage liver disease and represents an entity with high morbidity and mortality; and economic burden, Therefore, it is important that clinicians understand the treatment options for cholestatic liver diseases. This review addresses the pathophysiology of cholangiopathies, a general view of current treatments and their molecular targets, and a specific review of those groups of drugs. The objective is to provide clinicians with an overview of the current treatment of cholangiopathies based on evidence on its efficacy and safety.

show abstract

“…The regulation of NIK predominantly occurs post-translationally. Structurally, NIK encompasses four domains: a TRAF3-binding N-terminal region, a negative regulatory domain (NRD), a core kinase domain, and a C-terminal domain responsible for binding with proteins like IKKα and p100 [44][45][46].…”

Section: Non-canonical Nf-κb Pathwaymentioning

confidence: 99%

The Yin and Yang of IκB Kinases in Cancer

Abdrabou

2023

Kinases and Phosphatases

View full text Add to dashboard Cite

IκB kinases (IKKs), specifically IKKα and IKKβ, have long been recognized for their pivotal role in the NF-κB pathway, orchestrating immune and inflammatory responses. However, recent years have unveiled their dual role in cancer, where they can act as both promoters and suppressors of tumorigenesis. In addition, the interplay with pathways such as the MAPK and PI3K pathways underscores the complexity of IKK regulation and its multifaceted role in both inflammation and cancer. By exploring the molecular underpinnings of these processes, we can better comprehend the complex interplay between IKKs, tumor development, immune responses, and the development of more effective therapeutics. Ultimately, this review explores the dual role of IκB kinases in cancer, focusing on the impact of phosphorylation events and crosstalk with other signaling pathways, shedding light on their intricate regulation and multifaceted functions in both inflammation and cancer.

show abstract

Progress and Prospects of Non-Canonical NF-κB Signaling Pathway in the Regulation of Liver Diseases

Cited by 10 publications

References 97 publications

Current Therapies for Cholestatic Diseases

Current Therapies for Cholestatic Diseases

Current Therapies for Cholestatic Diseases

The Yin and Yang of IκB Kinases in Cancer

Contact Info

Product

Resources

About